Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3745703 | 1.00 | DPP4 (0.45) | DPP4DPP8DPP9DPP7KDM1A | |
| SCHEMBL3745710 | 1.00 | DPP4 (0.45) | DPP4DPP8DPP9DPP7KDM1A | |
| SCHEMBL3746364 | 0.88 | DPP4 (0.49) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL3747985 | 0.88 | DPP4 (0.54) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL3747993 | 0.88 | DPP4 (0.54) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL3746369 | 0.88 | DPP4 (0.49) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL3746362 | 0.88 | DPP4 (0.49) | DPP4DPP8DPP9DPP7KCNH2 | |
| SCHEMBL4748860 | 0.87 | DPP4 (0.46) | DPP4DPP8DPP9DPP7KDM1A | |
| SCHEMBL3750717 | 0.81 | DPP4 (0.49) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL3750722 | 0.81 | DPP4 (0.49) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | claimed |
| EP-1919854-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7834012-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.